This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Propofol-related infusion syndrome (PRIS) is a rare but catastrophic complication of propofol use. It is clinically characterized by metabolic acidosis, rhabdomyolysis, arrhythmias, myocardial failure, renal failure, and hepatomegaly, and may lead to death.1 Some risk factors are associated with PRIS, namely young age, critical illness, high fat intake, catecholamine or steroid use, inborn error of fatty acid oxidation, propofol doses exceeding 4–5 mg/kg/hour, and duration of use exceeding 48 hours.1 Some evidence also suggests that PRIS is related to a mitochondrial toxicity of propofol.2,3
Acknowledgment
The authors thank Éric Laflamme for his help revising this manuscript.
Footnotes
Author contributions: Dr. Martin Savard: drafting/revising the manuscript for content, including medical writing for content, study concept or design, analysis or interpretation of data. Dr. Nicolas Dupré: drafting/revising the manuscript for content, including medical writing for content. Dr. Alexis F. Turgeon: drafting/revising the manuscript for content, including medical writing for content. Dr. Richard Desbiens: drafting/revising the manuscript for content, including medical writing for content. Dr. Stephan Langevin: drafting/revising the manuscript for content, including medical writing for content. Dr. Denis Brunet: drafting/revising the manuscript for content, including medical writing for content.
Study funding: No targeted funding reported.
Disclosure: M. Savard and N. Dupré report no disclosures. A. Turgeon is a recipient of a research career grant (salary support) from the Fonds de la Recherche du Québec–Santé (FRQ-S), and from the Canadian Institutes of Health Research (CIHR). No financial support was received for this article. R. Desbiens, S. Langevin, and D. Brunet report no disclosures. Go to Neurology.org for full disclosures.
- Received December 19, 2012.
- Accepted in final form April 11, 2013.
- © 2013 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
- PRIS in mitochondrial disease : better safe than sorry?
- Banning propofol in patients with mitochondrial disorders is unwarranted.
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
